Navigation Links
Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962)
Date:11/6/2009

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- America's Specialty Medicines Companies (ASMC), an informal working group of mid-market and smaller innovator pharmaceutical companies, today expressed concerns about H.R. 3962, the "Affordable Health Care for America Act," introduced by House Democrats last Thursday. These smaller companies fear that the cumulative effect of a host of provisions in H.R. 3962 will hinder their efforts to bring new medicines to market.

From required rebates to mandated discounts to new regulations, H.R. 3962 repeatedly raises new barriers for small companies seeking to fund life-saving research. Unlike larger companies, smaller companies typically must use cash generated from the sale of their own products for research. Unfortunately, the bill starves them of those necessary revenues. Its new burdens will damage the viability of small companies, and ultimately, put at risk the health of future patients who need medicines that smaller companies are more likely to develop.

Smaller companies generate much of the innovation in the pharmaceutical industry. Their work ranges over the entire spectrum from drugs for some of the most common diseases like cancer and diabetes to those for smaller, underserved populations with rare diseases. Without smaller companies' investment in the research and development of breakthrough products, many patients would go without any effective treatment. In many cases, these very treatments contain costs by eliminating the need for more expensive care.

"Small pharmaceutical companies often bring needed specialty medications to market when no one else will. Unfortunately, H.R. 3962 would stifle that innovation and prevent those efforts. Ultimately, the patients who need these medicines will suffer most," said Steve Cannon, an attorney representing ASMC.

But the damage runs deeper. H.R. 3962 will cut off small drug companies' ability to bring drugs developed overseas to the U.S. market as well. Small companies frequently license U.S. rights to those drugs, conduct U.S. clinical trials on them, and seek U.S. approval of them. Much of that economic activity would stop under H.R. 3962 - hurting the U.S. economy, killing U.S. jobs, and depriving U.S. patients of needed drugs.

Despite our concerns, ASMC looks forward to continuing to work with Congress to produce health care legislation that will produce better care and better drugs for all Americans.

SOURCE America's Specialty Medicines Companies


'/>"/>
SOURCE America's Specialty Medicines Companies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):